[1] Trivedi PJ,Corpechot C,Pares A,et al.Risk stratification in autoimmune cholestatic liver diseases:Opportunities for clinicians and trialists. Hepatology,2016,63(2):644-659.
[2] EASL Clinical Practice Guidelines:management of cholestatic liver diseases. J Hepatol,2009,51(2):237-267.
[3] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015年). 实用肝脏病杂志,2016,19(6):771-781.
[4] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 中华肝脏病杂志,2015,23(11):810-820.
[5] Fontana RJ,Hayashi PH,Barnhart H,et al.Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol,2015,110(10):1450-1459.
[6] 中华医学会妇产科学分会产科学组. 妊娠期肝内胆汁淤积症诊疗指南(2015). 临床肝胆病杂志,2015,31(10):1575-1578.
[7] 中华医学会传染病与寄生虫病学分会,肝病学分会. 病毒性肝炎防治方案. 中华传染病杂志,2001,19(1):56-62.
[8] Karlsen TH,Folseraas T,Thorburn D,et al.Primary sclerosing cholangitis-a comprehensive review. J Hepatol,2017,67(6): 1298-1323.
[9] Yang T,Khan GJ,Wu Z,et al.Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases. Drug Discov Today,2019,24(1):112-128.
[10] Ovadia C,Seed PT,Sklavounos A,et al.Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers:results of aggregate and individual patient data meta-analyses. Lancet,2019,393(10174):899-909.
[11] Pollock G,Minuk GY.Diagnostic considerations for cholestatic liver disease. J Gastroenterol Hepatol,2017,32(7):1303-1309.
[12] EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol,2017,67(1):145-172.
[13] Marzorati S, Invernizzi P,Lleo A.Making sense of autoantibodies in cholestatic liver diseases. Clin Liver Dis,2016,20(1):33-46.
[14] Okazaki K,Uchida K,Koyabu M,et al.IgG4 cholangiopathy: current concept,diagnosis,and pathogenesis. J Hepatol,2014,61(3):690-695.
[15] Meeralam Y,Al-Shammari K,Yaghoobi M.Diagnostic accuracy of EUS compared with MRCP in detecting choledocholithiasis:a meta-analysis of diagnostic test accuracy in head-to-head studies. Gastrointest Endosc,2017,86(6):986-993.
[16] Corpechot C.Utility of noninvasive markers of fibrosis in cholestatic liver diseases. Clin Liver Dis,2016,20(1):143-158. |
